A Prospective, Single-center Investigation of the Impact of Antithrombotic Drugs and Cerebral Microbleeds on Cerebral Outcomes in Patients with Coronary Artery Stents
Not Applicable
- Conditions
- Ischemic heart disease treated by percutaneous coronary intervention
- Registration Number
- JPRN-UMIN000014882
- Lead Sponsor
- ational Cerebral and Cardiovascular Center, Division of Cardiovascular Medicine
- Brief Summary
The prevalence of intracerebral microbleeds (CMBs) was 33% (n=109), with a mean number of CMBs of 2.9+-3.6 (median 2, quartile range 1-3), of which 16 (15%) were multi-CMBs (>4). ICH occurred in 1 of 4 CMBs (1.1%), with no significant difference in ICH prevalence among the 3 groups. CMB was associated with all-cause mortality (non-CMB vs. CMB<5 vs. CMB>4, 3.6% vs. 12.0% vs. 6.3%, P=0.022).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 329
Inclusion Criteria
Not provided
Exclusion Criteria
1.Claustrophobia 2.Inadequate to be enrolled
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cerebral event including cerebral infarction, cerebral hemorrhage, subdural hematoma, epidural hematoma, subarachnoid hemorrhage and transient ischemic attacks after one year
- Secondary Outcome Measures
Name Time Method After one year, 1. cardiac or non-cardiac death 2. cardiac event including sudden death and coronary revascularizations 3. major bleedings by the ISTH criteria (international Society of Thrombosis and Hemostasis)